CD274 and neoplasm: The OAK trial found that patients receiving atezolizumab with high PD-L1 expression (≥ 1% PD-L1 on tumor cells or tumor-infiltrating immune cells (TIL)) in the tumor microenvironment (TME) had a better prognosis than those with low PD-L1 expression.